J9358 Injection fam-trastu deru-nxki 1mg
Also known as: fam-trastuzumab deruxtecan, Enhertu
Injection of fam-trastuzumab deruxtecan-nxki, 1 milligram. Antibody-drug conjugate combining trastuzumab variant with topoisomerase I inhibitor.
In Plain Language
breast cancer injection; antibody-drug combination
Clinical Context
Used for HER2-positive metastatic breast cancer. More potent antibody-drug conjugate with improved tolerability profile.
RVU Information
CPT J9358 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9358?
CPT J9358 (Injection fam-trastu deru-nxki 1mg) is a J Codes (Drugs) code. Injection of fam-trastuzumab deruxtecan-nxki, 1 milligram. Antibody-drug conjugate combining trastuzumab variant with topoisomerase I inhibitor.
How is J9358 administered?
CPT J9358 is administered by a healthcare provider, typically via injection or infusion. Used for HER2-positive metastatic breast cancer. More potent antibody-drug conjugate with improved tolerability profile. It is used by Oncology, Surgery, Internal Medicine.
When is CPT J9358 used?
Used for HER2-positive metastatic breast cancer. More potent antibody-drug conjugate with improved tolerability profile.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.